Optimizing Endpoints for GLP-1 RA Clinical Trial Success

DISCUSS YOUR PROTOCOL
Driving a Bike
 

Empowering Patient-Centric Research in Obesity, Diabetes, and Cardiovascular Health

As GLP-1 receptor agonists (GLP-1 RAs) revolutionize the treatment landscape for obesity, diabetes, and related cardiovascular complications, Signant leads the way in capturing critical patient-reported outcomes (PROs) data. Our cutting-edge electronic PRO (ePRO) solutions ensure your clinical trials generate high-quality, reliable evidence to support regulatory approvals and demonstrate real-world patient benefits.

Driving Successful Obesity Drug Development with GLP-1 Agonists
signanthealth.comhubfsobesity GLP-1 clinical trials

Driving Successful Obesity Drug Development with GLP-1 Agonists

READ THE BLOG →

Why Choose Signant Health for Your GLP-1 RA Trials?

1

Unparalleled Experience:

We've supported over 30 obesity clinical trials evaluating GLP-1 RAs, including pivotal studies leading to regulatory approvals, in addition to over 40 trials in both diabetes and cardiovascular disease.

Unparalleled Experience:
2

Global Reach: 

Our solutions for obesity clinical trials have engaged over 50,000 patients across 35 countries, with studies lasting up to 5 years.

Global Reach: 
3

Comprehensive ePRO Portfolio: 

We have experience in supporting a wide range of ePRO measures to assess aspects of health important to patients with these diseases including:

Health-related quality of life (HRQoL, e.g., SF-36, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)(EQ-5D-5L), Food craving (e.g., Control of Eating Questionnaire (CoEQ)), Mental health (e.g., Columbia-Suicide Severity Rating Scale (C-SSRS), Patient Health Questionnaire-9 (PHQ-9)) and other measures such as the Patient Global Impression of Severity/Change (PCIS/C).

Comprehensive ePRO Portfolio: 
4

Patient-Centric Design: 

Our user-friendly ePRO app not only provides an easy and quick way to collect patient-reported outcomes data, but it also helps to guide each patient through each stage of the study by providing up-to-date clinic visit schedules, visit reminders, study information including what to expect at each clinic visit, and easy to use TeleVisit functionality for remote follow up consultations.

Patient-Centric Design: 
man on smartphone

Tailored Solutions
for GLP-1 RA Research 

Whether you're studying weight loss efficacy, glycemic control, cardiovascular outcomes, or quality of life improvements, Signant Health's ePRO solutions deliver:

Robust data collection for primary and secondary endpoints 

Robust data collection for primary and secondary endpoints

Expert input from our team of 50+ clinicians and COA scientists to drive highest quality evidence generation

Expert input from our team of 50+ clinicians and COA scientists to drive highest quality evidence generation

Evidence generation to support for health technology assessments and economic evaluations

Evidence generation to support for health technology assessments and economic evaluations

24/7 global patient and site support

24/7 global patient and site support

Seamless integration of decentralized trial elements, such as eConsent, TeleVisits, and more.

Seamless integration of decentralized trial elements, such as eConsent, TeleVisits, and more.

Ensuring Success Through Technology, Science, Scale, and Service 

Successful clinical trials require more than just technology. Our approach combines four key elements to drive your GLP-1 RA studies to success: 
Solution

SOLUTION

Our leading eCOA solution provides comprehensive functionality adaptable to any study protocol, ensuring seamless data collection and management.

Science

SCIENCE

With a team of 50+ clinicians and COA scientists, we provide the scientific credibility and expertise needed to generate high-quality, reliable evidence that meets regulatory standards.

Scale

SCALE

Our robust architectural and operational capacity allows us to support large-scale obesity and diabetes clinical trials across the globe, currently hosting over 600 active ePRO trials.

Service

SERVICE

Experienced project teams, mature operational processes, 24/7 patient and site support, hardware logistics, and comprehensive translations and scale license management ensure smooth trial execution from start to finish.

Supporting 25% of novel drug approvals* across FDA and EMA

Signant Health's technology and services have supported a quarter of all regulatory authorizations for new active substances in their first indications across major global markets.

 

Let's discuss your protocol

WHO IS SIGNANT HEALTH


Signant Health is the evidence generation company, leveraging software, deep therapeutic and scientific knowledge, and operational expertise to deliver quality evidence across traditional, virtual, and hybrid trial models. For over 25 years, 600+ sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant’s comprehensive eClinical solutions. Our clinical outcome assessments (eCOA, clinician ratings, cognitive testing) and wearable digital health technologies powered by Ametris provide the industry's most comprehensive evidence generation capabilities, alongside EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.

*2021-2024. Regulatory authorization for new drug for first indication, defined as Novel Drug Approval by FDA, and Marketing Authorization for New Active Substance by EMA.